ORKA Quote, Financials, Valuation and Earnings

InflaRx NV has a net margin of -- compared to Oruka Therapeutics's net margin of -14092.9%. Oruka Therapeutics's return on equity of -- beat InflaRx NV's return on equity of -56.78%.

Oruka Therapeutics has a consensus price target of $39.86, signalling upside risk potential of 218.86%. On the other hand InflaRx NV has an analysts' consensus of $9.17 which suggests that it could grow by 697.1%. Given that InflaRx NV has higher upside potential than Oruka Therapeutics, analysts believe InflaRx NV is more attractive than Oruka Therapeutics.

Oruka Therapeutics has a beta of 0.664, which suggesting that the stock is 33.629% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.924%.

Oruka Therapeutics has a quarterly dividend of $19.36 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oruka Therapeutics pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Oruka Therapeutics quarterly revenues are --, which are smaller than InflaRx NV quarterly revenues of -$450. Oruka Therapeutics's net income of -$28.6M is lower than InflaRx NV's net income of -$5.4M. Notably, Oruka Therapeutics's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics is -- versus 372.88x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

LENZ Therapeutics has a net margin of -- compared to Oruka Therapeutics's net margin of --. Oruka Therapeutics's return on equity of -- beat LENZ Therapeutics's return on equity of --.

Oruka Therapeutics has a consensus price target of $39.86, signalling upside risk potential of 218.86%. On the other hand LENZ Therapeutics has an analysts' consensus of $42.63 which suggests that it could grow by 66.24%. Given that Oruka Therapeutics has higher upside potential than LENZ Therapeutics, analysts believe Oruka Therapeutics is more attractive than LENZ Therapeutics.

Oruka Therapeutics has a beta of 0.664, which suggesting that the stock is 33.629% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Oruka Therapeutics has a quarterly dividend of $19.36 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Oruka Therapeutics pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.

Oruka Therapeutics quarterly revenues are --, which are smaller than LENZ Therapeutics quarterly revenues of --. Oruka Therapeutics's net income of -$28.6M is lower than LENZ Therapeutics's net income of -$12.7M. Notably, Oruka Therapeutics's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics is -- versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

PetMed Express has a net margin of -- compared to Oruka Therapeutics's net margin of -1.33%. Oruka Therapeutics's return on equity of -- beat PetMed Express's return on equity of 0.37%.

Oruka Therapeutics has a consensus price target of $39.86, signalling upside risk potential of 218.86%. On the other hand PetMed Express has an analysts' consensus of $3.75 which suggests that it could fall by -10.5%. Given that Oruka Therapeutics has higher upside potential than PetMed Express, analysts believe Oruka Therapeutics is more attractive than PetMed Express.

Oruka Therapeutics has a beta of 0.664, which suggesting that the stock is 33.629% less volatile than S&P 500. In comparison PetMed Express has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.429%.

Oruka Therapeutics has a quarterly dividend of $19.36 per share corresponding to a yield of 0%. PetMed Express offers a yield of 0% to investors and pays a quarterly dividend of $0.30 per share. Oruka Therapeutics pays -- of its earnings as a dividend. PetMed Express pays out -166.63% of its earnings as a dividend.

Oruka Therapeutics quarterly revenues are --, which are smaller than PetMed Express quarterly revenues of $53M. Oruka Therapeutics's net income of -$28.6M is lower than PetMed Express's net income of -$707K. Notably, Oruka Therapeutics's price-to-earnings ratio is -- while PetMed Express's PE ratio is 419.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics is -- versus 0.35x for PetMed Express. Usually stocks with elevated PS ratios are considered overvalued.